CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1665-1670

  Zagorianakou, N ^a   Stefanou, D ^a   Makrydimas, G ^a   Zagorianakou, P ^a   Briasoulis, E ^a   Karavasilis, B ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

CD44s; ER; MIB1; Ovarian cancer; p53; PCNA; PR

Indexed keywords

CYCLINE; HERMES ANTIGEN; KI 67 ANTIGEN; PROTEIN P53; STEROID RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; BORDERLINE TUMOR; CANCER CELL; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTADENOMA; DISEASE MARKER; EPITHELIUM; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; OVARIAN NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3242662669     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ponta H, Wainright D and Herrlich P: Molecules in focus: the CD44 protein family. Inter J Biochem Cell Biol 30: 299-305, 1998.
2. Bajorath J: Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Prot Struct Funct Genet 39: 103-111, 2000.
3. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
4. Ponta H, Sleeman J, Dall P, Moll J, Sherman L and Herlich P: CD44 isoforms in metastatic cancer. Inv Metast 14: 82-86, 1995.
5. Johnson P, Maiti A, Brown KL and Li R: A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response? Biochem Pharmacol 59: 455-465, 2000.
6. Pure E and Cuff CA: A crucial role for CD44 in inflammation. Trends Mol Med 7: 213-221, 2001.
7. Gunthert U: CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 184: 47-63, 1993.
8. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U and Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160-12164, 1992.
9. Jalkanen S, Joensuu H, Soderstrom KO et al: Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 87: 1835-1840, 1991.
10. Tempfer C, Lösch A, Heinzl H, Häusler G, Hanzal E, Kölbl H, Breitenecker G and Kainz Ch: Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6, and CD44v7-8 in human breast cancer. Eur J Cancer 32(11): 2023-2025, 1996.
11. Stokes GN, Shelton JB, Zahn CM and Kendall BS: Association of CD44 isoform immunohistochemical expression with myometrial and vascular invasion in endometrioid endometrial carcinoma. Gynecol Oncol 84: 58-61, 2002.
12. Speiser P, Wanner C, Tempfer C, Mittelbock M, Hanzal E, Bancher-Todesca D, Gitch G, Reinthaller A and Kainz C: CD44 is an independent prognostic factor in early-stage cervical cancer. Int J Cancer 74: 185-188, 1997.
13. Morris SF, O'Hanlon DM, Mclaughlin R, Mchale T, Connoly GE and Given HF: The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study. EJSO 27: 527-531, 2001.
14. Tokumo K, Kodama J, Seki N, Miyagi Y, Yoshinuchi M and Kudo T: CD44 exon v6 is not implicated in the progression and metastasis of endometrial cancer. Cancer Letter 125(1-2): 221, 1999.
15. Saegusa M, Hashimura M, Machida D and Okayasu I: Down-regulation of CD44 standard and variants isoforms during the progression of uterine cervical tumors. J Pathol 187: 173-183, 1999.
16. Givehchian M, Wörner S, Sträter J, Zöller M, Heuschen U, Lehnert T, Herfarth C and von Knebel Doeberitz M: No evidence for cancer-related CD44 splice variants in primary and metastatic colorectal cancer. Eur J Cancer 34: 1099-1104, 1998.
17. Cannistra SA, Kansas GS, Niloff J, De Franzo B, Kim Y and Ottensmeir C: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 53: 3830-3838, 1993.
18. Kayastha S, Freedman AN, Piver MS, Mukamalla J, Romero-Guittirez M and Werness BA: Expression of the Hyaluronan receptor, CD44s, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 5: 1073-1076, 1999.
19. Ross JS, Sheehan CE, Williams SS, Malfetano JH, Szyfelbein WM and Kallakury BV: Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol 116(1): 122-8, 2001.
20. Lesley J, Hyman R and Kincade PW: CD44 and its interactions with extracellular matrix. Adv Immunol 54: 271-335, 1993.
21. Kokenyesi R: Ovarian carcinoma cells synthesize both condroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstizial matrix. J Cellular Biochem 83: 259-270, 2001.
22. Gardner MJ, Jones LMH, Catterall JB and Turner GA: Expression of cell adhesion molecules on ovarian tumor cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Letters 91: 229-234, 1995.
23. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-6, 1991.
24. Zolota V, Tsamandas A, Melachrinou M, Batistatou A and Scopa C: Expression of CD44 protein in renal carcinomas: association with p53 expression. Urol Oncol 7: 13-17, 2002.
25. Zagorianakou N, Ioachim E, Mitselou A, Kitsou E, Zagorianakou P, Makrydimas G and Agnantis NJ: Glycoprotein CD44s expression in normal, hyperplastic and neoplastic endometrium. An immunohistochemical study including correlation with p53, steroid receptor status and proliferative indices (PCNA, MIB1). Eur J Gynecol Cancer 4(6): 500-4, 2003.
26. Kurman RJ: Blaunstain's Pathology of the Female Genital Tract, 4th ed. Springer, New York, 1994.
27. Levine AJ: The tumor suppressor genes. Annu Rev Biochem 62: 623-651, 1993.
28. Johnston SRD and Gore ME: Caelyx®: Phase II studies in ovarian cancer. Eur J Cancer 37: S8-S14, 2001.
29. National Cancer Institute. SEER Cancer Statistics Review 1973-1997, 2001.
30. Statistisches Bundesamt. Fascherie 12 (Gesundheitswesen), Reihe 4: Todesursachenstatistik in Dtl. Stuttgart, Metzler Poeschel, 1996.
31. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA: A Cancer J Clin 51: 15-36, 2001.
32. Kurman RJ and Trimble CL: The behaviour of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 12: 120-127, 1993.
33. Auersperg N, Edelson MI, Mok SC, Johnson SW and Hamilton TC: The biology of ovarian cancer. Semin Oncol 25: 281-304, 1998.
34. Cannistra SA: Cancer of the ovary. N Engl J Med 329: 1550-1559, 1993.
35. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Anderson J and Ottensmeir C: CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 13(8): 1912-21, 1995.
36. Uhl-Steidl M, Muller-Holzner E, Zeimet AG, Adolf GR, Daxenbichl, Marth C and Dapunt O: Prognostic value of CD44v splice variant expression in ovarian cancer. Oncology 52(5): 400-6, 1995.
37. Schroder W, Rudlowski C, Biesterfeld S, Knobloch C, Hauptmann S and Rath W: Expression of CD44 (v5-v10) splicing variants in primary ovarian cancer and lymph node metastasis. Anticancer Res 19 (5B): 3901-6, 1999.
38. Saegusa M, Machida D, Hashimura M and Okayasu I: CD44 Expression in benign, premalignant and malignant ovarian neoplasms: relation to tumor development and progression. J Pathol 189: 326-337, 1999.
39. Anreder M, Freeman S, Megori A, Halabi S and Marrogi A: p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms. Arch Pathol Lab Med 123: 310-316, 1999.
40. Kamura T, Sakai K, Kaku T, Kobayashi H, Mitsumoto M, Tsueyoshi M and Nakao H: Comparison of p53 and CD44 variant 6 expression between paired primary and recurrent ovarian cancer: an immunohistochemical analysis. Oncol Rep 6(1): 97-101, 1999.
41. Werteim I, Muto M, Welch W, Bell D, Berkowitz R and Mok C: p53 gene mutation in human borderline epithelial ovarian tumors. J Nat Cancer Inst 86: 1549-1551, 1994.